Member Info for shareguard

Europe no doubt will blame Astra Zeneca for missing Lab mice.

2p or not 2p that is the ?

Even Shakespeare must have been a Scancell share holder to write these words.
sort of fits my ride with them.
To be, or not to be, that is the question: Whether 'tis nobler in the mind to suffer The slings and arrows of outrageous fortune, Or to take Arms against a Sea of troubles, And by opposing end them: to die, to sleep; No more; and by a sleep, to say we end The heart-ache, and the thousand natural shocks That Flesh is heir to? 'Tis a consummation Devoutly to be wished. To die, to sleep, To sleep, perchance to Dream; aye,

Krafty thats my concern why name Scancell in the press before the official release of such news, did the reporter who first named the universal vaccine from Scancell in a news coup infer in her report that the said firm was scancell for some kudos points and not actually said by cepi at all.
Know i am have not picked the team damp baton.

I know but doesnt mean that nano cant be used i was refering to the oral bit a litttle excerpt from it just some info thats all in context with discussion.

Challenges of oral vaccine delivery
Although oral vaccines have multiple potential advantages over conventional methods,
there remain challenges in developing vaccines which utilise this administration route.
An ideal oral vaccine delivery system would have to safely deliver the antigen through
to the intestine, where it can transport across the mucosal barrier and transfect antigenpresenting cells to generate an immune response. There are two key obstacles which
any oral vaccine needs to overcome to deliver its payload and generate an adequate
immune response. There are certain features of Nuvec® which indicate it could
overcome these hurdles:
1) The harsh environment of the gastrointestinal (GI) tract: The stomach is a highly
acidic environment, whilst the GI tract has a number of enzymes (DNases, Rases,
proteases) which can degrade nucleic acid or protein-based antigens. Nuvec® loaded
with DNA/RNA is suitable for lyophilisation (freeze drying) and can be loaded onto an
acid-resistant capsule. This can protect the particle and vaccine antigens from
degradation in the stomach. Furthermore, lyophilisation could enable storage at
ambient temperatures. Lipid nanoparticles, another form of vaccine delivery system, are
not suitable for lyophilisation and therefore have to be stored at cooler temperatures
as a liquid or semi-solid formulation.
2) The movement and clearance of intestinal matter: The muscular contractions of the
small intestine move matter through the GI tract. If the vaccine is not able to bind to and
transfect the mucosal cells lining the epithelium of the intestines it can be expelled
without delivering its payload. The spikes on the surface of Nuvec are coated with
positively charged PEI. This is expected to support Nuvec's adhesive properties and
enable the particle to bind to and subsequently transfect mucosal cells as it passes along
the GI tract.

Mention this before John Chiplin chairman of both Scancell and N4p no smoke without fire they are working on oral delivery but one for the future probably but wont surprise me if there is some crossover between the two companys.
Long read oral bit from page 20.

https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf

Maybe someone in USA waking up to the science.

Max/Berm correct buried here ...
In December 2020, we announced the selection of our lead COVID-19 vaccine candidate, SN14. In light of the newly identified variants of the SARS CoV-2 virus, which are becoming increasingly prevalent and which may become more important in the transmission and community spread of COVID-19, more recent data has suggested that another of our lead candidates, SN15 (or SCOV1 for future reference), MAY confer even better protection against the virus than SN14. SCOV1 reproducibly elicited higher-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins and further studies are underway to test SCOV1 against the variants identified in South Africa and Brazil.
Though it only says may and further studies underway so not cut and dry and will need a rns in its own right before confirmation in my opinion.

The best we can hope for from this presentation is a roadmap (tongue in cheek) no price sensitive news can come out otherwise the regulators will want to know why it wasnt released beforehand.
The phone at scancell will have been ringing every 5 mins for latest info so why not give a presentation not a de-ramp pure good Pr and everyones happy.
Having said that a lot can be gleamed from body language or maybe a slip up so who knows we will soon find out.

Could we be in Apples eye a very appealing thought this report suggests they buy out a company on a regular basis but dont like paying top dollar compared to other big names.
Link below.
https://www.bbc.co.uk/news/business-56178792
If we are on their radar who knows but like too think if someone makes a move for us others will follow, my shares are for sale but in measured quantities above what we sit at right now .
I have this dream that a tug of war would ensue for us in many multiples of 10p.

My guess for what its worth there will be no earth shattering news otherwise it would have been rns at the earliest opportunity,
they must be inundated from all the press coverage from investors and the press for news so much so that a presentation with maybe some timelines to look forward too would seem to be the logical solution to keep everybody happy without distracting the team from their important work.

Posted this last year Samsung invest money into early pharmas with good science exposure in South Korea may lead to contacts to the right funding for phase 1 from a unlikely source. Watch the link below company called Cytodyn recieved 60 million from Samsung.

RE: Virus infections24 Feb 2020 15:37
Funny enough i was thinking the same was researching another stock last night come across this video which was repeated on Bloomberg tv last night. Contains 3 stocks the middle one is seeing machines the one i hold, but watched them all the first one got a drug for aids in phase 3 and using similar for cancer not looked at the science but seems similar to scancell. What struck me was how well funded they are from Samsung of all people based in south korea if Scancells tech can be used for virus who knows the money could roll in from a source no one would have thought of, nothing like a crisis to loosen the purse strings you have to look at wars suddenly money is no object.

https://youtu.be/J4A9k1blk60
Regards

Hi all interesting discussion for me as many years ago (1998) i was diagnosed with melanoma and it was cut off.
Many years of worrying about a dark freckle/mole i thought was changing and they cut it off i was told by the skin doctor that i should try not to worry too much although you did have melanoma your body was already dealing with it and would have gone on its own. At the time just thought she was sick of seeing me but in recent years have read that this can happen. Would be a fantastic development if this could be triggered at will.

https://www.dailymail.co.uk/debate/article-9260193/Professor-BRENDAN-WREN-predicts-vaccine-rollout-bring-end-chaos-Covid-19-pandemic.html

The possibility of a lifelong vaccine against Covid-19 now seems genuinely feasible. Scientists at Nottingham University believe their breakthrough ‘universal jab’, which targets the nucleocapsid [core of the virus] as well as the spike protein, could be ready for distribution next year.

If that is successful, it will bring a permanent end to the chaos and fear of the pandemic. We can expect such a vaccine to be effective against all variants because the core of the virus, unlike its outer ‘spike proteins’, mutates slowly.

It is reasonable to hope that a single shot, with no need for booster injections, will deliver immunity for the vast majority of people.
Kerching!!!

Just maybe they have been told no mention of Scancell to stay under the radar for a blockbuster deal they are doing with a top pharma with a gagging order non discloser agreement aaahhhh just dreaming..

The charts can be followed to a degree, but they dont work all the time they have to have a herd following them to make it work unless you are part of that herd, (and there are lots of share clubs my friend was in one) that follow these rules but come unstuck when news to the contrary trips them up. They are not for me but upto each individual on following them but they are a tool if you work with others.

The charts only work if that share has a following, that buy and sell the share in question so this makes the share follow the predicted rule. Its all market driven the more people buy it goes up and sell goes down it cant help but follow that rule you only have to look at the recent moves in gamestop and yesterday silver. So again if enough people follow the rules the share will move in a predicted pattern only comes unstuck if you get your candlesticks shoved up you backside by a larger group or some unexpected major news no hocus pocus about it.

Hi Morning all ''Been looking and thinking hard as to the 15% drop in SP we have seen since last week, and I just don"t buy that the sells we have seen yesterday for example have anything to do with timelines discussed by JC''
C7 I agree think what we are seeing is a pull back after results nothing more, still would have dropped if we had no interview the mentality of buy on rumour sell on news happens all the time another of my shares Seeing Machines did the the same yesterday. If enough traders follow the rule it becomes self full filling .

Yes Ruck 8 years is a long time i am in my 6th year gradually investing more but 6 months is a very short time in shares (Redmile) watch this space...... When you have millions invested they wont allow no action regarding deals i bet its like waiting for a bus you wait ages then 3 turn up.

I disagree Kash (not about red wine)I also think there will be news soon, it will be what delivery system along with phase 1 trial
while its everyone's interpretation what is significant news i think it could well propel us into the 20's with maybe some more money from the government.
Who knows this statement from interims:-
AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been FURTHER ENGINEERED using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly KILL tumour cells. The Company has entered into three non-exclusive research agreements with leading antibody technology companies to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology.

Could lead to a deal landing anytime soon.
So much going on particular with covidity and AvidiMab who knows what rns will land any day, its not bad to say they enjoyed the discussion it was hardily off topic we are all keen for news no harm in getting excited over a tweet :-)

Kashdog's been on the cheese :-)